Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2024-06-12 00:00:00 ET · period of report 2024-06-12 · accession 0001628280-24-027797 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-12 | 2024-06-12 | VIR | De Backer Marianne | CEO, Dir | J - Other | $0.00 | -53.1K | 625.3K | -8% | $0 | |
| I | 2024-06-12 | 2024-06-12 | VIR | De Backer Marianne | CEO, Dir | J - Other | $0.00 | +53.1K | 53.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-12 | J | D | 53,118 | $0.00 | 625,339 | D See Footnote | — | — | (F2) The shares are held in the name of the Ureel-De Backer Family Trust, of which the reporting person and her spouse are Trustees. |
| 2 | Common | Common Stock | 2024-06-12 | J | A | 53,118 | $0.00 | 53,118 | I | — | — |